Draxis Pharma LLC Balance Sheet

As at 31st March,	Note No	2014	2014		2013	
		USD	Rs.'000	USD	Rs.'000	
I. EQUITY AND LIABILITIES Shareholders' Funds	(2) Sajasujayayayayada, algesta o	etermineljene pastepine, men bestemlig og freder	ite managa da lata ta mana ilipatika lah managa lata ka	terik jamentajaren az albagi heriologiak idalek dib	akusta filosopi Esta kasini filosofi sa tatu in Estaga a tin	
Share Capital	1 , 1	250,100	11,639	250,100	11,639	
Reserves & Surplus	2	(495)	3,315	(352)	1,920	
	1 -	249,605	14,954	249,748	13,559	
		249,605	14,954	249,748	13,559	
II. ASSETS						
Non-current assets	-	1		1		
Non-current investments	3 _	2,262	135	2,345	127	
		2,262	135	2,345	127	
Current Assets			1			
Cash & cash equivalents	4	343	21	403	22	
Short-term loans and advances	5	247,000	14,798	247,000	13,410	
	F	247,343	14,819	247,403	13,432	
	_	249,605	14,954	249,748	13,559	

Rajneesh Gupta Head Accounts Place: Noida Date: 22nd May 2014

Draxis Pharma LLC Statement of Profit and Loss

For the year ended 31st March,	Note No	2014		2013	
		USD	Rs.'000	USD	Rs.'000
aattaaluutta kantifen taa niidettä televaljat kautaan moisialalai jastaksi kakakalukan hunnettä elekakalukaisia kataalaikiliki kai josti kit REVENUE	di diphermanya dipanaman		k nakina hingunah hindiga dan kalipiya ku nipatayah n	Anna is na figh a bhaille air agus an	ia, a mangapit ya ayi isibali aki katalanga at ay iya bayd
Total Revenue		-	-	-	
EXPENSES					
Other expenses	6	143	9	131	7
Total Expenses		143	9	131	
Profit/(Loss) before Tax Tax Expense:		(143)	(9)	(131)	(7)
- Current Tax (including Wealth Tax) - Deferred Tax Charge/(Credit)		-	-	-	
Profit/(Loss) after Tax		(143)	(9)	(131)	(7)

Rajneesh Gupta Head Accounts Place: Noida Date: 22nd May 2014

Draxis Pharma LLC Cash Flow Statement

For the year ended 31st March,		2014		2013	
	USD	Rs.'000	USD	Rs.'000	
A. Cash flow arising from Operating Activities :			kaanina kalenda ja		
Net profit / (Loss) before tax Adjustment for:	(143)	(9)	(131)	(7	
Share of (Profit) / loss from Partnership Firm	83	5	71	4	
Net Cash Inflow/(Outflow) in course of Operating Activities	(60)	(4)	(60)	(3)	
B. Cash Flow arising from Investing Activities:		and the second s	. Address of the second		
Loan to Holding Co Draxis Pharma Inc.	-	_	(7,000)	(380	
Net Cash Inflow/(Outflow) in course of Investing Activities		-	(7,000)	(380)	
C. Foreign Currency Translation Difference		2		26	
Net Increase in Cash & Cash equivalents (A+B+C) Add: Cash & Cash Equivalents at the beginning of Year	(60) 403	(1) 22	(7,060) 7,463	(358)	
Cash & Cash Equivalents at the close of the Year	343	21	403	22	

- 1) Cash flow statement has been prepared under the indirect method as set out in the Accounting Standard 3 (AS-3)-"Cash Flow Statements", notified by the Central Government under the Companies(Accounting Standard) Rules, 2006.
 2) Figures in brackets represent Cash Outflow
- 3) Previous Year's figures have been regrouped/rearranged wherever found necessary to conform to this year's classification.

Rajneesh Gupta Head Accounts Place: Noida

Date: 22nd May 2014

Draxis Pharma LLC

Notes to financial statements as at 31st March,	2014		2013	
	USD	Rs.'000	USD	Rs.'000
			·	3
1,000 SHARE CAPITAL	-combabilità de la completa de la comp			naminantsionitaministisio
Authorised				
Equity Share Capital	-	-	-	-
(1,000 units of no par value)				
•	-		-	-
Issued, Subscribed & Paid Up				
Equity Share Capital	250,100	11,639	250,100	11,639
1,000 units of no par value (Previous Year 1,000 units)				
	250,100	11,639	250,100	11,639

- 1.1) The Company has only one class of units referred to herein as equity shares. Each holder of equity shares is entitled to one vote per share.
- 1.2) In the event of liquidation of the Company, the holders of equity shares shall be entitled to receive all of the remaining assets of the Company, after distribution of all preferential amounts, if any. Such amounts will be in proportion to the number of shares of equity shares held by the stockholders.
- 1.3) The details of shares held by holding/ultimate holding company and/or their subsidiaries/associates:

	2014		2013	
	No. of Shares	USD	No. of Shares	USD
Jubilant HollisterStier Inc., USA - the Holding Company				
Equity Shares at no par value	1,000	250,100	1,000	250,100
			1. 1. 1.	
1.4) The details of shareholders holding more than 5% shares as at 31st March,2014 is set out below:				
	201		201	13
	No. of Shares	% Holding	No. of Shares % Holding	
	No. or Sitates	70 Holding	No. or Shares	70 Holding
Jubilant HollisterStier Inc., USA - the Holding Company	1,000	100	1,000	100
1.5) The reconciliation of the number of shares outstanding as at 31st				
March,2014 and 31st March,2013 is set out below: Particulars	2014		2013	
Particulars	No. of Shares	Rs.'000	No. of Shares	Rs.'000
	Hor or Shares	1131 000	Itor or onarcs	1131 000
Numbers of shares at the beginning	1,000	11,639	1,000	11,639
Add: Shares issued during the year	-	-		· -
Numbers of shares at the end	1,000	11,639	1,000	11,639
	USD	Rs.'000	USD	Rs.'000
2. RESERVES AND SURPLUS				
Foreign Currency Translation Reserve				
Opening Balance	1	1,938		1,085
Addition: Effect of foreign exchange rate variation during the year		1,404		854
Total	-	3,343	·	1,938
Surplus (Deficit)				
Opening Balance	(352)	(19)		(12)
Add: Net Profit (Loss) after tax transferred from Statement of Profit and Loss	(143)	(9)	(131)	(7)
	(495)	(28)	(352)	(19)
Total	(495)	3,315	(352)	1,920

Draxis Pharma LLC

Notes to financial statements as at 31st March,	2014	2014		2013	
and the construction of the first transfer of the second o	USD	Rs.'000	USD	Rs.'000	
3. NON CURRENT INVESTMENTS (At Cost) Trade Investments Investment in Equity Instruments (Fully Paid up Equity Shares) Investment in Subsidiary Companies:	. જેવી ખુશ્કાની કરવા અને કહેવી તે કોઇ પ્રકાશની પહોંચની કોઇ પ્રકાશની હોઇ પ્રકાશની કોઇ પ્રકાશની હોઇ પ્રકાશની હોઇ	teretarri hari teretarri kanta k	den es désires en descriptions de désires de la condicionada de la con	den gela eta gela eta eta eta eta eta eta eta eta eta et	
- Jubilant HollisterStier General Partnership (0.01% Stake)	2,345	141	2,417	131	
Add / (less): Share of Profit / (loss) from Partnership Firm	(83)	(5)	(71)	(4)	
	2,262	135	2,345	127	
4. CASH AND BANK BALANCES					
Cash and cash equivalents Balances with banks: - On Current Accounts	343	21	403	22	
	343	21	403	22	
5. SHORT TERM LOANS AND ADVANCES					
- Loans to related parties(unsecured,considered good)	247,000	14,798	247,000	13,410	
	247,000	14,798	247,000	13,410	

Draxis Pharma LLC

Notes to financial statements for the year ended 31st March,	2014		2013	
Grant and supplication for the analysis of agreement of the control when by the agreement of the control of the	USD	Rs.'000	USD	Rs.'000
The Control of	diska politikationationanikanikanik	Aparaktineittä onikaajastulujujujujujujuj	ન્દ્રોને કરો જાતી એ જેવારો દોકા તેવારો સામાનો કરાયા છે.	distribute di lattra de colonia e e e e e e e e e e e e e e e e e e e
Bank Charges	60	4	60	3
Share of loss from Partnership Firm	83	5	71	4
	143	9	131	7